Tenaya Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Tenaya Therapeutics, Inc. (TNYA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $1.32 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-05
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $670.00K, a 9.48% increase year-over-year.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $654.00K, a 9.73% increase year-over-year.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $640.00K, a 13.04% decline year-over-year.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $625.00K, a 39.32% decline year-over-year.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.47M, a 27.07% decline from fiscal 2024.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $3.39M, a 8.27% increase from fiscal 2023.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $3.13M, a 39.45% increase from fiscal 2022.
- Tenaya Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $2.25M, a 111.09% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $670.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.32M 10-Q · filed 2026-08-05 | $1.96M derived: sum of 3 quarters · filed 2026-08-05 | $2.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $654.00K 10-Q · filed 2026-05-06 | $1.29M derived: sum of 2 quarters · filed 2026-05-06 | $1.92M derived: sum of 3 quarters · filed 2026-05-06 | $2.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $640.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.26M derived: sum of 2 quarters · filed 2026-03-11 | $1.88M derived: sum of 3 quarters · filed 2026-08-05 | $2.47M 10-K · filed 2026-03-11 |
| 2025-09-30 | $625.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.24M derived: sum of 2 quarters · filed 2026-08-05 | $1.83M 10-Q · filed 2025-11-10 | $2.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $612.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.21M 10-Q · filed 2026-08-05 | $1.94M derived: sum of 3 quarters · filed 2026-08-05 | $2.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $596.00K 10-Q · filed 2026-05-06 | $1.33M derived: sum of 2 quarters · filed 2026-05-06 | $2.36M derived: sum of 3 quarters · filed 2026-05-06 | $3.19M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $736.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.77M derived: sum of 2 quarters · filed 2026-03-11 | $2.59M derived: sum of 3 quarters · filed 2026-03-11 | $3.39M 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.85M derived: sum of 2 quarters · filed 2025-11-10 | $2.65M 10-Q · filed 2025-11-10 | $3.46M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $823.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.63M 10-Q · filed 2025-08-06 | $2.43M derived: sum of 3 quarters · filed 2025-08-06 | $3.23M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $802.00K 10-Q · filed 2025-05-07 | $1.61M derived: sum of 2 quarters · filed 2025-05-07 | $2.40M derived: sum of 3 quarters · filed 2025-05-07 | $3.18M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $806.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.60M derived: sum of 2 quarters · filed 2025-03-10 | $2.38M derived: sum of 3 quarters · filed 2025-03-10 | $3.13M 10-K · filed 2025-03-10 |
| 2023-09-30 | $796.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.57M derived: sum of 2 quarters · filed 2024-11-06 | $2.33M 10-Q · filed 2024-11-06 | $3.06M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $776.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.53M 10-Q · filed 2024-08-08 | $2.27M derived: sum of 3 quarters · filed 2024-08-08 | $2.98M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $754.00K 10-Q · filed 2024-05-14 | $1.49M derived: sum of 2 quarters · filed 2024-05-14 | $2.21M derived: sum of 3 quarters · filed 2024-05-14 | $2.67M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $736.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $1.45M derived: sum of 2 quarters · filed 2024-03-18 | $1.91M derived: sum of 3 quarters · filed 2024-03-18 | $2.25M 10-K · filed 2024-03-18 |
| 2022-09-30 | $715.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.18M derived: sum of 2 quarters · filed 2023-11-08 | $1.51M 10-Q · filed 2023-11-08 | $1.83M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $463.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $795.00K 10-Q · filed 2023-08-09 | $1.12M derived: sum of 3 quarters · filed 2023-08-09 | $1.43M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $332.00K 10-Q · filed 2023-05-10 | $653.00K derived: sum of 2 quarters · filed 2023-05-10 | $962.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.23M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $321.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $630.00K derived: sum of 2 quarters · filed 2023-03-08 | $893.00K derived: sum of 3 quarters · filed 2023-03-08 | $1.06M 10-K · filed 2023-03-08 |
| 2021-09-30 | $309.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $572.00K derived: sum of 2 quarters · filed 2022-11-10 | $743.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $434.00K 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $171.00K 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |